CD34 Antikörper (AA 32-290)
Kurzübersicht für CD34 Antikörper (AA 32-290) (ABIN3021124)
Target
Alle CD34 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
- 
    - 
                                            Bindungsspezifität
- AA 32-290
- 
                                            Sequenz
- SLDNNGTATP ELPTQGTFSN VSTNVSYQET TTPSTLGSTS LHPVSQHGNE ATTNITETTV KFTSTSVITS VYGNTNSSVQ SQTSVISTVF TTPANVSTPE TTLKPSLSPG NVSDLSTTST SLATSPTKPY TSSSPILSDI KAEIKCSGIR EVKLTQGICL EQNKTSSCAE FKKDRGEGLA RVLCGEEQAD ADAGAQVCSL LLAQSEVRPQ CLLLVLANRT EISSKLQLMK KHQSDLKKLG ILDFTEQDVA SHQSYSQKT
- 
                                            Kreuzreaktivität
- Human, Ratte
- 
                                            Produktmerkmale
- Polyclonal Antibodies
- 
                                            Aufreinigung
- Affinity purification
- 
                                            Immunogen
- Recombinant fusion protein containing a sequence corresponding to amino acids 32-290 of human CD34 (NP_001020280.1).
- 
                                            Isotyp
- IgG
 
- 
                                            
- 
    
- 
    - 
                                            Applikationshinweise
- WB,1:500 - 1:2000,IHC,1:50 - 1:200,IF,1:50 - 1:200
- 
                                            Beschränkungen
- Nur für Forschungszwecke einsetzbar
 
- 
                                            
- 
    - 
                                            Format
- Liquid
- 
                                            Buffer
- PBS with 0.02 % sodium azide,50 % glycerol, pH 7.3.
- 
                                            Konservierungsmittel
- Sodium azide
- 
                                            Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 
                                            Handhabung
- Avoid freeze / thaw cycles
- 
                                            Lagerung
- -20 °C
- 
                                            Informationen zur Lagerung
- Store at -20°C. Avoid freeze / thaw cycles.
 
- 
                                            
- 
    - 
                                            : "Early missed abortion is associated with villous angiogenesis via the HIF-1α/VEGF signaling pathway."    in: Archives of gynecology and obstetrics, Vol. 298, Issue 3, pp. 537-543, (2018)         (PubMed).        
 : "Enriched housing promotes post-stroke functional recovery through astrocytic HMGB1-IL-6-mediated angiogenesis." in: Cell death discovery, Vol. 3, pp. 17054, (2017) (PubMed).
 : "miR-320a mediates doxorubicin-induced cardiotoxicity by targeting VEGF signal pathway." in: Aging, Vol. 8, Issue 1, pp. 192-207, (2016) (PubMed).
 
 
- 
                                            : "Early missed abortion is associated with villous angiogenesis via the HIF-1α/VEGF signaling pathway."    in: Archives of gynecology and obstetrics, Vol. 298, Issue 3, pp. 537-543, (2018)         (PubMed).        
- 
    - CD34
- 
                                            Andere Bezeichnung
- CD34
- 
                                            Hintergrund
- The protein encoded by this gene may play a role in the attachment of stem cells to the bone marrow extracellular matrix or to stromal cells. This single-pass membrane protein is highly glycosylated and phosphorylated by protein kinase C. Two transcript variants encoding different isoforms have been found for this gene.,CD34,CD34 Molecule,GIG3,MORT1,Cancer,Tumor biomarkers,Cell Biology & Developmental Biology,Immunology & Inflammation,CD markers,Neuroscience,Cell Type Marker,Stem Cells,Endothelial Progenitors,Hematopoietic Progenitors,Mesenchymal Stem Cells,Cardiovascular,Heart,Cardiogenesis,Neuron marker,CD34
- 
                                            Molekulargewicht
- 35 kDa/40 kDa
- 
                                            Gen-ID
- 947
- 
                                            UniProt
- P28906
 Target
- 
                    
 
                                     
                                     
                                    